Biogen Inc. cash flow to debt ratio of 31.73% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Biogen Inc.'s free cash flow has decreased 18.48% from $2.52B last year to $2.05B, signaling decreasing performance

Biogen Inc.'s debt to equity ratio is 0.44, which means that the company's assets are healthy financed, signaling financial stability.

Biogen Inc.'s debt has increased relative to shareholder equity from 0.40 last year to 0.44 today, signaling weakened financials

Biogen Inc. has a net debt to EBITDA ratio of 1.01x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Biogen Inc.'s interest coverage ratio of 4.47 indicates that earnings with good margin can cover interest payments on company debt

Biogen Inc.'s profit margin has decreased (50.24%) in the last year from 16.87% to 8.39%, signaling decreasing performance

Biogen Inc.'s short-term assets of $8.97B exceed its short-term liabilities of $3.35B

Biogen Inc.'s return on assets of 2.60% is lower than the 5.00% threshold, indicating inefficient asset utilization

Biogen Inc.'s return on equity of 4.52%, is lower than 15.00%, indicating bad performance

Biogen Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Biogen Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Biogen Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Biogen Inc. has a free cash flow yield of 6.70%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Biogen Inc.'s yearly earnings has decreased 20.76% since last year from $1.63B to $1.29B, signaling decreasing performance

Biogen Inc.'s yearly revenue has increased 1.39% since last year from $9.68B to $9.81B, signaling increasing performance

ROIC 4.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Biogen Inc.'s 3-year revenue CAGR of -1.20% is negative, indicating declining revenue over the past 3 years

Biogen Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Biogen Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Biogen Inc. is overvalued relative to its fair value price of 70.78 based on Discounted Cash Flow model

Biogen Inc. has an earnings yield of 2.73%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Biogen Inc. is overvalued relative to its fair value price of 121.05 based on EBITDA multiple model

Biogen Inc. has an EV/EBITDA ratio of 10.88x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Biogen Inc. is overvalued relative to its fair value price of 135.17 based on Earnings Fair Value model

Biogen Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Biogen Inc. has a price-to-book ratio of 1.62x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Biogen Inc. has a price-to-sales ratio of 3.08x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue